2024 Incb001158

Incb001158

Author: oxwb

August undefined, 2024

WebINCB001158 (CB-1158) is an investigational first-in-class, novel small molecule arginase inhibitor. Arginase is an enzyme that suppresses the immune-mediated destruction of tumors by depleting ...

A phase I/II study of safety and efficacy of the arginase inhibitor ...

Web• INCB001158 is a small-molecule arginase inhibitor that restores arginine levels and alleviates myeloid-derived immunosuppression in the tumor microenvironment Primary Endpoints •Safety, tolerability, and RP2D of INCB001158 in combination with gemcitabine/cisplatin •ORR Secondary Endpoints •DOR, DCR, PFS Other Endpoints PK ... WebApr 16, 2024 · Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219791 Prospectus Supplement... glenwell road glengormley

INCB001158 and Epacadostat and Pembrolizumab on Solid …

WebDec 17, 2024 · Median DOR for INCB001158 plus gemcitabine/cisplatin was 5.8 months; median PFS was 8.5 months. Based on these data, the researchers concluded that the addition of INCB001158 to the standard gemcitabine/cisplatin backbone was tolerable, did not result in significant additional toxicity, and demonstrated modest clinical activity in … WebMay 10, 2024 · The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy. WebPresentation details: Date: Available starting on Friday, January 15 at 5:00 a.m. Pacific … body shop robina town centre

Calithera Biosciences to Present New Data on Two Oncology

Phase I study of the arginase inhibitor INCB001158

WebNov 28, 2024 · Drug: INCB001158 Drug: Epacadostat Drug: Pembrolizumab Study Type Interventional Enrollment (Actual) 5 Phase Phase 2 Phase 1 Contacts and Locations This section provides the contact details for those conducting the study, and information on where this study is being conducted. Study Locations United States Alabama WebAug 24, 2024 · Explanation A problem occurred during the IPL of a partition. Response The … body shop rochester nyWebMay 6, 2024 · INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma Sponsor Incyte Corporation (Industry) Overall Status Completed CT.gov ID NCT03837509 Collaborator (none) 15 Enrollment 29 Locations 3 Arms 30.3 Actual Duration (Months) 0.5 Patients Per Site 0 … glen wesman paintings

"WebApr 12, 2024 · A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Latest version (submitted July 20, 2024) on ClinicalTrials.gov A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. " - Incb001158

Incb001158

History of Changes for Study: NCT03314935 - ClinicalTrials.gov

Methods: This open-label phase 1/2 study evaluated the safety, tolerability, and antitumor activity of INCB001158 in pts with advanced or metastatic solid tumors. In phase I, dose escalation of INCB001158 (50, 75, and 100 mg twice daily [BID]) was used to determine the recommended phase II dose (RP2D) of INCB001158 + gemcitabine/cisplatin. WebTreatment Agent INCB001158, Pembrolizumab Description This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. Resources and Links Phone Number: 1-877-MDA-6789 clinicaltrials.gov NCT No: NCT02903914

Did you know?

WebThe purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in … WebJan 20, 2024 · INCB001158 is a new inhibitory molecule of arginase, currently under investigation in a phase I clinical trial both as a single agent and in combination with "classic" ICI in patients with...

WebINCB001158, Pembrolizumab Description This study is an open-label Phase 1/Phase 2 … Web1621 - Phase 1 Study of the Arginase Inhibitor INCB001158 (1158) Alone and in …

WebOct 5, 2024 · INCB001158 Arginase Inhibitor Immuno-oncology Program. INCB001158 is being evaluated in multiple clinical trials for the treatment of patients with solid tumors both as a monotherapy, and in combination with immunotherapies and chemotherapy. INCB001158 is being developed as part of a collaboration and license agreement with … WebBank Identification Number (“BIN”) or Issuer identification number (“IIN”) is the first six …

WebSep 29, 2024 · INCB001158 (CB-1158) is an investigational first-in-class, novel small …

WebOct 1, 2024 · Phase I study of the arginase inhibitor INCB001158 (1158) alone and in … glen wessel rapid cityhttp://www.calithera.com/wp-content/uploads/2024/01/Arginase-1158-203-Poster.pdf glen westmore surrey county councilWebFeb 24, 2024 · incb001158. Showing 1 - 3 of 3. Trials per page: STUDY. CONDITIONS. INTERVENTIONS. LOCATIONS. LAST UPDATED Advanced Solid Tumors, Metastatic Solid Tumors Trial in Chuo Ku, Kashiwa (Retifanlimab, INCB001158, Retifanlimab + INCB001158) Completed. Advanced Solid Tumors; Metastatic Solid Tumors ... body shop richmond caWebINCB001158; INCB-001158; NUMIDARGISTAT [INN] NUMIDARGISTAT [USAN] NUMIDARGISTAT [WHO-DD] Resources. Common Chemistry. i. Inxight Drugs. i. NCATS GSRS Full Record. i. NCI Thesaurus. i. PubChem. i. Note. UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does … glen westphal obituaryWebNavigate to DrugBank.com to check out our commercial products, use cases and more! body shop rockford ilWebMay 20, 2024 · INCB001158 Pharmacology Indication Not Available Build, train, & validate predictive machine-learning models with structured datasets. See how Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events & improve clinical decision support. Learn more Pharmacodynamics Not Available Mechanism of action Not … glen weyl microsoft researchWebJan 11, 2024 · Title: A phase I/II study of safety and efficacy of the arginase inhibitor … body shop rochester indiana